Earnings digests and industry comparisons for Japan's biggest listed companies.
237 reports(page 6 of 20)
Sapporo disclosed on October 7, 2026 that the Fair Trade Commission conducted an unexpected dawn raid over allegations of illegal price-fixing. This investigation targets four major manufacturers and poses significant risks to corporate value.
Kirin announced its subsidiary, Kirin Beer, was subjected to a forced raid by the Fair Trade Commission today on suspicion of violating the Antimonopoly Act. The investigation focuses on potential anti-competitive practices in business partnerships and pricing. While the specific impact on financial results remains unclear, the company pledges full cooperation with authorities.
Mitsubishi Materials (5711) will consolidate domestic cutting tool sales with wholly-owned subsidiary MOLDINO via a simplified absorption split. The new entity, Mitsubishi Materials Tools, launches April 1, 2027, aiming to boost decision speed and customer competitiveness.
Peptide Dream has reached a key milestone with US pharma giant MSD in its PCC program, validating the versatility of its PDPS platform. The undisclosed fee was already factored into forecasts for the year ending December 2026.
Nissan Chemical is establishing a new wholly owned subsidiary in China with a registered capital of approximately 5 billion yen (210 million yuan). This move aims to strengthen its local supply base for semiconductors and secure long-term earnings growth.
ABC-Mart has raised its full-year earnings forecast for the fiscal year ending February 2027. Consolidated sales are now projected to reach 403 billion yen, with operating income up 6.0% from the prior year.
Asahi Group Holdings announced that subsidiary Asahi Beer will undergo a mandatory investigation by the Japan Fair Trade Commission over suspected antitrust violations. The specific financial impact remains unclear as markets assess the regulatory risks.
Otsuka completed its rolling submission for the biologics license application of IgA nephropathy drug VOYXACT in the US. While there is no immediate impact on fiscal 2026 earnings, this marks a key step toward long-term corporate value growth.
Sanyo Shokai revised its FY2027 dividend forecast, cutting the year-end payment to 31 yen. This adjustment reflects a strategic shift toward capital reduction via share buybacks rather than operational weakness.
Kawasaki updated its Group Vision 2030 during an Oct 6 progress report, setting a sales target exceeding 3.3 trillion yen and operating profit above 330 billion yen. The company plans to accelerate growth investments through approximately 2 trillion yen in capital raises.
Resonac has lowered the conversion price of its outstanding bonds by approximately 1.5% to 4,444.1 yen to reflect the completion of its petrochemical business spinoff. This adjustment finalizes the equity value realignment for existing convertible bondholders.
Meiji announced on Oct. 6, 2026, that it will transfer its subsidiary Nippon Kankitsu to Yoshimura Food to exit a deficit-ridden segment. The move aims to concentrate resources on dairy and confectionery while minimizing financial impact on the March 2027 fiscal year.
